

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)

FINANCIAL STATEMENTS

September 30, 2025



Gurseley | Schneider LLP
CERTIFIED PUBLIC ACCOUNTANTS & ADVISORS

CONTENTS

	<u>Pages</u>
INDEPENDENT AUDITOR'S REPORT	1 - 2
FINANCIAL STATEMENTS	
Statement of Financial Position	3
Statement of Activities and Changes in Net Assets	4
Statement of Functional Expenses	5 - 6
Statement of Cash Flows	7
Notes to Financial Statements	8 - 18

Independent Auditor's Report

To the Board of Directors
International Myeloma Foundation
Studio City, California

Opinion

We have audited the accompanying financial statements of the International Myeloma Foundation (the Foundation), which comprise the statement of financial position as of September 30, 2025, and the related statements of activities and changes in net assets, functional expenses, and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Foundation as of September 30, 2025, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Statements* section of our report. We are required to be independent of the Foundation and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for one year after the date that the financial statements are available to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Gursey | Schneider LLP

January 28, 2026
Los Angeles, California

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Statement of Financial Position
September 30, 2025

ASSETS

CURRENT ASSETS

Cash and cash equivalents	\$	1,443,052
Investments, at fair value		12,287,905
Contributions, program grants, and other receivables, current portion		1,715,722
Prepaid expenses		945,055
Total Current Assets		16,391,734

OTHER ASSETS

Contributions, program grants, and other receivables, net of current portion		345,000
Property and equipment, net		849,145
Intangible assets, net		44,439
Right-of-use asset, operating lease		640,200
Security deposits		20,607
Total Other Assets		1,899,391

TOTAL ASSETS	\$	18,291,125
---------------------	-----------	-------------------

LIABILITIES AND NET ASSETS

LIABILITIES

Accounts payable and accrued expenses	\$	2,026,099
Right-of-use liability, operating lease, current portion		187,478
Deferred program and educational grant revenues		4,792,677
Total Current Liabilities		7,006,254

OTHER LIABILITIES

Right-of-use liability, operating lease, net of current portion		484,750
Gift annuity obligation		45,534
TOTAL LIABILITIES		7,536,538

NET ASSETS

Without donor restrictions		10,001,258
With donor restrictions		753,329
TOTAL NET ASSETS		10,754,587
TOTAL LIABILITIES AND NET ASSETS	\$	18,291,125

See Accompanying Notes to Financial Statements

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Statement of Activities and Changes in Net Assets
For the Year Ended September 30, 2025

	Without Donor Restrictions	With Donor Restrictions	Total
REVENUES AND SUPPORT			
Educational and program grants	\$ 7,131,611	\$ 1,235,000	\$ 8,366,611
General contributions	1,152,175	1,520,700	2,672,875
Contributed non-financial assets	30,000	-	30,000
Clinical trials and research revenue	6,225,114	-	6,225,114
Change in split interest agreements	-	(5,307)	(5,307)
Support group income	15,655	-	15,655
Fundraising events, net of direct benefit to donors \$506,565	-	636,723	636,723
Investment income, net of advisory fees of \$67,917	1,000,172	12,482	1,012,654
	15,554,727	3,399,598	18,954,325
Transfer to annuity assets	(7,810)	7,810	-
Net assets released from restrictions	2,976,495	(2,976,495)	-
TOTAL REVENUES AND SUPPORT	18,523,412	430,913	18,954,325
FUNCTIONAL EXPENSES			
Program expenses	15,762,544	-	15,762,544
General supporting expenses	1,239,936	-	1,239,936
Fundraising	1,449,358	-	1,449,358
TOTAL FUNCTIONAL EXPENSES	18,451,838	-	18,451,838
CHANGE IN NET ASSETS	71,574	430,913	502,487
NET ASSETS - Beginning of year	9,929,684	322,416	10,252,100
NET ASSETS - End of year	\$ 10,001,258	\$ 753,329	\$ 10,754,587

See Accompanying Notes to Financial Statements

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Statement of Functional Expenses
For the Year Ended September 30, 2025

	Advocacy	Clinical Meetings	Education and Awareness	InfoLine	Information Mailings	International	Myeloma Today	Nurse
Bank fees	\$ 278	\$ 313	\$ 2,436	\$ 243	\$ 66	\$ 541	\$ 234	\$ 626
Conference and meetings	22,257	125,517	458,847	-	-	312,538	-	371,561
Depreciation and amortization	11,203	225	109,961	11,173	11,001	11,458	11,162	11,489
Dues and subscriptions	40,940	25	4,206	136	35	596	102	572
Information Technology	4,470	3,997	83,939	4,136	1,080	9,552	3,897	9,247
Insurance	1,473	803	17,560	1,968	526	8,054	1,550	8,222
Office	2,200	1,841	158,134	1,743	457	5,812	1,662	9,731
Payroll	154,772	66,198	1,564,982	248,318	55,508	162,157	205,470	195,347
Postage and shipping	123	-	2,438	-	6,707	-	40,081	16,791
Printing and publications	3,488	525	242,166	-	-	2,366	36,070	50,704
Professional services	101,855	25,936	224,330	51,215	1,277	116,024	4,206	87,014
Rent	410	1,370	28,578	4,823	10,624	3,354	2,711	2,125
Research grants awarded	-	-	-	-	-	32,000	-	-
Taxes	238	314	2,070	203	56	530	200	519
Telephone	1,508	798	7,870	795	212	1,742	909	6,169
Travel	18,127	112,487	146,920	-	-	119,486	-	38,825
Total	\$ 363,342	\$ 340,349	\$ 3,054,437	\$ 324,753	\$ 87,549	\$ 786,210	\$ 308,254	\$ 808,942

(Continued on next page)

See Accompanying Notes to Financial Statements

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Statement of Functional Expenses
For the Year Ended September 30, 2025

(Continued from previous page)

	Patient and Family Seminars	Research	Support Groups	Website	Total Program Expenses	General Supporting Expenses	Fundraising Expenses	Total Expenses
Bank fees	\$ 1,402	\$ 4,091	\$ 1,236	\$ 361	\$ 11,827	\$ 1,411	\$ 1,496	\$ 14,734
Conference and meetings	680,641	1,135,733	317,912	-	3,425,006	77,130	131,549	3,633,685
Depreciation and amortization	12,269	14,790	11,974	-	216,705	12,300	12,234	241,239
Dues and subscriptions	846	4,927	23,140	295	75,820	1,018	28,184	105,022
Information Technology	22,326	71,941	17,078	9,116	240,779	23,857	28,199	292,835
Insurance	12,589	58,690	8,125	2,376	121,936	24,944	9,957	156,837
Office	11,798	57,058	30,411	219,181	500,028	263,737	70,280	834,045
Payroll	935,162	639,838	944,953	321,231	5,493,936	720,565	814,834	7,029,335
Postage and shipping	16,654	89	6,374	-	89,257	4,733	20,916	114,906
Printing and publications	17,868	2,536,831	10,705	-	2,900,723	900	100,436	3,002,059
Professional services	50,366	702,741	34,804	7,700	1,407,468	24,687	123,533	1,555,688
Rent	19,917	15,005	8,013	5,238	102,168	68,749	56,710	227,627
Research grants awarded	-	180,000	-	-	212,000	-	-	212,000
Taxes	1,155	3,486	1,107	309	10,187	1,154	1,298	12,639
Telephone	4,578	23,540	10,505	1,168	59,794	4,629	6,862	71,285
Travel	79,944	300,578	73,169	5,374	894,910	10,122	42,870	947,902
Total	\$ 1,867,515	\$ 5,749,338	\$ 1,499,506	\$ 572,349	\$ 15,762,544	\$ 1,239,936	\$ 1,449,358	\$ 18,451,838

See Accompanying Notes to Financial Statements

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Statement of Cash Flows
For the Year Ended September 30, 2025

CASH FLOWS FROM OPERATING ACTIVITIES:	
Change in net assets	\$ 502,487
Adjustments to reconcile change in net assets to net cash provided by operating activities:	
Change in split interest agreements	5,307
Depreciation and amortization	241,239
Amortization of right of use asset	4,096
Realized and unrealized gains, net	(682,451)
(Increase) decrease in assets:	
Contributions, program grants, and other receivables	(767,822)
Prepaid expenses	(207,203)
Security deposits	800
Increase (decrease) in liabilities:	
Accounts payable and accrued expenses	(511,668)
Deferred program and educational grants	<u>1,585,667</u>
NET CASH PROVIDED BY OPERATING ACTIVITIES	<u>170,452</u>
CASH FLOWS FROM INVESTING ACTIVITIES	
Purchases of investments	(8,549,347)
Proceeds from sale of investments	6,825,846
Payment to annuitants	(7,810)
Purchases of property and equipment, net	<u>(118,039)</u>
NET CASH USED FOR INVESTING ACTIVITIES	<u>(1,849,350)</u>
NET DECREASE IN CASH AND CASH EQUIVALENTS	(1,678,898)
CASH AND CASH EQUIVALENTS	
Beginning of Year	<u>3,121,950</u>
End of Year	<u>\$ 1,443,052</u>

See Accompanying Notes to Financial Statements

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 1 - NATURE OF ORGANIZATION

Founded in 1990, the International Myeloma Foundation (IMF) is the world's first and largest organization dedicated exclusively to multiple myeloma. The IMF is committed to improving the quality of life of patients while advancing toward prevention and a cure. Guided by its four founding pillars: Research, Education, Support, and Advocacy—the IMF unites researchers, clinicians, patients, care partners, and institutions worldwide to strengthen the myeloma community and improve outcomes for those affected.

Research: The IMF is dedicated to finding a cure for multiple myeloma through a robust portfolio of research initiatives. The International Myeloma Working Group (IMWG), which evolved from the IMF's Scientific Advisory Board established in 1995, is the world's most prestigious collaborative network of more than 375 myeloma researchers. The IMWG advances patient outcomes through global collaboration and the development of critically appraised, consensus clinical guidelines followed worldwide. The IMF's Black Swan Research Initiative focuses on closing the gap between long-term remission and cure, while the annual Brian D. Novis Research Grant Program supports the most promising research projects led by both junior and senior investigators. In addition, the IMF's Nurse Leadership Board, comprised of nurses from leading myeloma treatment centers, develops evidence-based recommendations to advance excellence in myeloma nursing care. To further advance equity in myeloma research, the IMF, in partnership with the Cobb Foundation (the research arm of the National Medical Association), created the *Medical Student Scholars for Health Equity in Myeloma* program. This initiative pairs medical students, many from Historically Black Colleges and Universities, with leading myeloma experts to conduct research on health disparities in myeloma and present their findings at the National Medical Association's Annual Meeting. The program helps cultivate the next generation of physician-researchers while deepening understanding of myeloma's impact on underserved communities.

Education: The IMF delivers timely, evidence-based education through webinars, seminars, and workshops featuring leading myeloma scientists and clinicians, including international myeloma physicians, who bring both cutting-edge research and real-world expertise to patients, care partners, and families. The IMF also maintains a comprehensive library of more than 100 educational publications for patients, care partners, and healthcare professionals. These resources are regularly updated, free of charge, and available in English and select additional languages.

Support: Studies show that social support can greatly improve the quality of life for cancer patients. The IMF's InfoLine provides compassionate, accurate answers to myeloma-related questions via phone and email. The IMF also maintains a network of myeloma support groups, led by resilient and compassionate volunteers, patients, care partners, and nurses, whose dedication strengthens communities and offers vital peer support. Our team works closely to support these leaders in many ways, ensuring they have the resources, training, and guidance needed to sustain these groups effectively. Additionally, the IMF introduced Myelo, a 24/7 generative AI assistant with extensive knowledge of multiple myeloma, including symptoms, diagnosis, treatment options, clinical trials, and management strategies, offering an innovative new avenue for guidance and support.

Advocacy: The IMF empowers thousands of individuals each year to take action on issues critical to the myeloma community. In the U.S., the IMF leads coalitions representing patients' interests at both federal and state levels. Globally, the IMF's Global Myeloma Action Network works to improve patient access to treatment and care worldwide.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Financial Presentation - The accompanying financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America ("GAAP").

Use of Estimates - The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.

Classes of Net Assets - The Foundation recognizes contributions, including unconditional promises to give, as revenue in the period in which they are received. Revenues, gains, expenses, and losses are classified based on the existence or absence of donor-imposed restrictions. Accordingly, net assets of the Foundation and changes therein are classified and reported as follows:

- *Without Donor Restrictions* - Net assets are not subject to donor-imposed stipulations. Net assets without donor restrictions may be designated for specific purposes by actions of the board of directors or may otherwise be limited by contractual agreements with outside parties.
- *With Donor Restrictions* - Net assets that are subject to donor-imposed restrictions that limit the use of their contributions. Donor restrictions may result in temporarily restricted net assets, where the use of contributions is limited by donor-imposed stipulations that either expire by the passage of time or when used for specified purposes. Donor restrictions may also result in permanently restricted net assets, where the donor stipulates that resources are to be maintained permanently but permits the Foundation to expend all of the income (or other economic benefits) derived from the donated assets. The Foundation did not have any permanently restricted net assets at September 30, 2025.

Cash and Cash Equivalents - The Foundation considers highly liquid investments with a maturity of three months or less when purchased to be cash and cash equivalents. This amount includes short-term certificates of deposit and money market funds.

Revenue Recognition - The Foundation has multiple revenue streams that are accounted for as contributions, educational and program grants, and reciprocal exchange transaction involving clinical trials and special events.

Contributions - Contributions are measured at fair value and are recognized when the donor makes a promise to give that is, in substance, unconditional. Contributions that are restricted by the donor or provided for future periods are reported as increases in net assets with donor restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions. Contributions which are conditioned upon the occurrence of future events or achievement of milestone accomplishments are deferred and recognized once the event or milestone accomplishment has been fulfilled.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (CONTINUED)

Educational and Program Grants - Program grants may consist of conditional awards where the Foundation is obligated to provide a certain event or program or complete a charitable activity. Certain program grants contain milestone or other progress measures that require attainment of certain threshold prior to the application and award of subsequent funding. Contracts that contain such contingencies are accounted for as contingent awards. Revenue from contingent award contracts is recognized when the condition or milestone is met. Other program grants without milestones are accounted for as contributions, when awarded.

Clinical Trials Revenue - The Foundation contracts with several pharmaceutical companies to conduct various clinical trials related to finding treatments for multiple myeloma through a contracted network of research institutions. The Foundation is responsible for executing multi-year contracts to perform clinical trials in accordance with the terms set forth in the contracts, collecting data, providing administrative support, collaborating with research institutions to produce a final report, and collecting and remitting payments as a fiscal agent. The number of enrolled subjects as well as milestone achievement, and expenses incurred to date may be used to measure the delivery of services to the pharmaceutical companies. Revenues from clinical trials are recognized when pre-established milestones are met.

Special Events Revenue - The Foundation organizes various special events as a fundraising effort. Revenues collected for these events consist of both the exchange and non-exchange components. Any payments collected in advance of the event taking place are reported as deferred revenue, and the revenue is recognized when the condition is satisfied, generally when the event takes place.

Contributions, Program Grants, and Other Receivables - Receivables represent primarily amounts due from grant partners for research, educational, or other program grants, or amounts due from donors for general support contributions. The Foundation considers these receivables fully collectible; accordingly, no allowance for doubtful accounts is required. Included in other receivables are \$295,287 of government grants receivable for payroll tax recoveries due under the Employee Retention Tax Credit, which was received in full after year-end.

Receivables are expected to be received as follows:

<u>Years ending September 30.</u>	
2026	\$ 1,715,722
2027	115,000
2028	115,000
2029	<u>115,000</u>
Total	<u>\$ 2,060,722</u>

These amounts are not discounted to reflect present value as such adjustment would not be material.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (CONTINUED)

Credit Losses - The Foundation evaluates the collectability of financial assets measured at amortized cost in accordance with FASB Accounting Standards Codification (“ASC”) 326, *Financial Instruments—Credit Losses*. Financial assets subject to this guidance primarily consist of other receivables.

The Foundation estimates expected credit losses over the contractual life of these financial assets using a current expected credit loss (“CECL”) model. The estimate is based on relevant information, including historical loss experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the receivables. Historical loss information is adjusted for qualitative factors when management determines that such adjustments are necessary to reflect current and expected future conditions. Financial assets are written off against the allowance for credit losses when the Foundation determines the asset is uncollectible. Recoveries, if any, are recorded when received.

Investments - Investments are stated at fair value with unrealized gains and losses on investments resulting from fair value fluctuations recorded in the statements of activities in the period that such fluctuations occur. Purchases and sales of investments are recorded on the trade date. Dividend income is recorded based on the record date. Interest income is recorded as earned on an accrual basis. Dividend income is recorded upon the ex-dividend date. Bond premiums and discounts are amortized to the first call date using a method that approximates the effective interest method. Realized gains and losses are recorded upon disposition of securities. Investment income and realized and unrealized gains and losses are recognized as unrestricted net assets unless their use is temporarily or permanently restricted by donors to a specified purpose or future period.

Property and Equipment - Purchased property and equipment is capitalized at cost or, if contributed, at fair value at the date of contribution. Ordinary repairs and maintenance are expensed in the year incurred. Computer software developed for internal use is capitalized. Depreciation of property and equipment is computed using the straight-line method based upon the estimated useful lives of the assets as follows:

Computer software and equipment	3 - 5 years
Furniture and equipment	5 years
Website and CRM database	5 years
Leasehold improvements	Lesser of useful life or lease term

Intangible Assets - Intangible assets consist of legal costs paid to secure the rights to various Foundation trademarks used both domestically and internationally. The costs of these intangible assets are being amortized on a straight-line basis over the life of the trademark and are stated at cost net of accumulated amortization. The Foundation estimates a ten (10) year useful life for its trademarks.

Impairment of Long-Lived Assets - Long-lived assets such as property and equipment, software and website development costs, trademarks and other intangible assets are reviewed for events or changes in circumstances, which indicate that their carrying value may not be recoverable. Further, long-lived assets held for sale are to be stated at the lower of cost or fair value less costs to sell.

Contributed Non-Financial Assets - Contributed services are recognized by the Foundation if the services received (a) increase or enhance long-lived assets or (b) require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided by donation. During the year ended September 30, 2025, the Foundation received \$30,000 of donated services for technology services that is included as contributed non-financial assets in the statement of activities.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (CONTINUED)

Functional Expenses - The costs of providing the various programs and activities have been summarized on a functional basis in the statement of activities. Expenses that can be identified with a specific program or supporting service are charged directly to the related program or supporting service. Expenses that are associated with program and supporting service are allocated based on estimates determined by management. The Foundation uses employee salaries based on time survey allocation as a measure to allocate indirect costs for compensation and benefits among program or supporting services, and space occupancy survey as a basis to allocate occupancy and general overhead related indirect costs.

Income Taxes - The Foundation is a not-for-profit organization that is exempt from income taxes under Section 501(c)(3) of the Internal Revenue Code and Section 23701(d) of the California Revenue and Taxation Code.

The Foundation evaluates its tax positions and recognize a liability for any positions that would not be considered “more likely than not” to be upheld under a tax authority examination. If such issues exist, the Foundation’s policy will be to recognize any tax liability so recorded, including applicable interest and penalties, as a component of income tax expense. The Foundation did not recognize any amount of tax, interest, and penalties associated with uncertain tax positions.

The Foundation’s federal income tax and informational returns for tax years 2022 and subsequent years remain subject to examination by the Internal Revenue Service. The returns for California remain subject to examination by the California Franchise Tax Board for years 2021 and subsequent.

Foreign Currency - The Foundation conducts operations in foreign countries and purchases goods and services at prices denominated in various foreign currencies. The Foundation’s functional currency for all operations worldwide is the U.S. dollar. Nonmonetary assets and liabilities are translated at historical rates and monetary assets and liabilities are translated at exchange rates in effect at the end of the year. Statement of activity accounts are translated at actual or average rates for the year. Gains and losses resulting from foreign currency transactions are included in the current statement of activities. Aggregate foreign currency translation and transaction losses included in the statement of activities are not material. On September 30, 2025, the Foundation holds less than \$5,000 of foreign currency denominated assets and no foreign currency denominated liabilities.

Concentration of Credit Risk - Financial instruments that potentially expose the Foundation to a concentration of credit risk consist primarily of cash and cash equivalents, investments, and contributions.

The Foundation maintains its cash and cash equivalents with high-credit, quality financial institutions. The Federal Deposit Insurance Corporation (“FDIC”) insures cash up to \$250,000 per institution and the Securities Insurance Corporation (“SIPC”) protects investments up to \$500,000 per investor. In the normal course of operations, such cash and investment balances exceed the FDIC and SIPC insurance limits. However, the Foundation has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk on cash and investment.

Three industry partners accounted for approximately 48% of educational grant support during the year ended September 30, 2025. No other resource provider contributed more than 10% of total grant support during the year. Three industry partners accounted for approximately 45% of contributions receivable, and one individual accounted for an additional 26% as of September 30, 2025.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - (CONTINUED)

Leases – The Foundation determines if an arrangement is a lease at inception. Right-of-use ("ROU") assets represent the Foundation's right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term.

The Foundation uses its own estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments, as the rate implicit in the lease is not readily available for such leases.

The Foundation's lease term for purposes of the computation of the present value of minimum lease payments may include options to extend or terminate the lease when it is reasonably certain that it will exercise that option. The Foundation accounts for the lease and non-lease components as separate lease component.

Subsequent Events - Management has reviewed subsequent events through January 28, 2026, the date that the financial statements were available to be issued.

NOTE 3 - LIQUIDITY AND AVAILABILITY

Financial assets consist of the Foundation's cash and cash equivalents, investments, and receivables. The following table summarizes the Foundation's financial assets as of September 30, 2025, reduced by amounts not available for general use within one year.

Cash and cash equivalents	\$	1,443,052
Investments, at fair value		12,287,905
Contributions, program grants, and other receivables		<u>2,060,722</u>
		15,791,679
Less assets unavailable within one year:		
Contributions, program grants, and other receivables, non-current		(345,000)
Assets with donor restrictions		<u>(753,329)</u>
		<u>\$ 14,693,350</u>

The Foundation has an investment policy authorized by the board of directors that provides guidance and oversight for the management of cash and investments. The policy provides that the Foundation maintain an adequate level of cash to meet on-going operational and liquidity requirements. All liquid assets are invested in cash, cash equivalents and marketable securities at September 30, 2025. Management believes the Foundation has sufficient liquid net assets to meet its obligations for the following year.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 4 - INVESTMENTS

The Foundation’s investments are reported at fair value in the accompanying statement of financial position. Fair value is defined as the price that would be received upon selling an investment in an orderly transaction to an independent buyer in the principal or most advantageous market of the investment. A three-tiered hierarchy is employed to maximize the use of observable market data and minimize the use of unobservable inputs, and to establish classification of fair value measurements for disclosure purposes. Inputs refer broadly to the assumptions that market participants would use in pricing the asset, including assumptions about risk. Inputs may be observable or unobservable. Observable inputs are inputs that reflect assumptions market participants would use in pricing the asset developed based on market data obtained from sources independent of the reporting entity. Unobservable inputs are inputs that reflect the reporting entity’s own assumptions about the assumptions market participants would use in pricing the asset developed based on the best information available.

The three-tier hierarchy of inputs is summarized in the three broad levels listed below.

- Level 1: Observable inputs that reflect unadjusted quoted prices for identical assets or liabilities traded in active markets.
- Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.
- Level 3: Inputs that are generally unobservable. These inputs may be used with internally developed methodologies that result in management’s best estimate of fair value.

Investments consist of the following at September 30, 2025:

	Fair value	Cost or Amortized Cost
	<u> </u>	<u> </u>
Equities	\$ 3,512,282	\$ 1,933,868
Mutual funds	2,642,200	2,382,941
ETF and closed end funds	2,875,990	2,347,537
Fixed income	<u>3,257,433</u>	<u>3,262,727</u>
 Total investments	 <u>\$ 12,287,905</u>	 <u>\$ 9,927,073</u>

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 4 - INVESTMENTS - (CONTINUED)

As of September 30, 2025, the Foundation's investments were classified by level within the valuation hierarchy as follows:

	Fair Value Hierarchy			Total
	Level 1	Level 2	Level 3	
Equities	\$ 3,512,282	\$ -	\$ -	\$ 3,512,282
Mutual funds	2,642,200	-	-	2,642,200
ETF and closed end funds	2,875,990	-	-	2,875,990
Fixed income	2,075,499	1,181,934	-	3,257,433
Total	\$ 11,105,971	\$ 1,181,934	\$ -	\$ 12,287,905

Investment income for the year ended September 30, 2025 is summarized as follows:

Interest and dividends	\$ 398,120
Realized and unrealized gains, net	682,451
Management fees	(67,917)
	\$ 1,012,654

NOTE 5 - PROPERTY AND EQUIPMENT

Property and equipment consist of the following at September 30, 2025:

Computer equipment	\$ 185,994
Computer software	1,664,483
Furniture and equipment	74,489
Leasehold improvements	18,755
	1,943,721
Less accumulated depreciation	(1,094,576)
	\$ 849,145

During the year ended September 30, 2025, the IMF disposed of \$67,573 of fully depreciated property and equipment.

Depreciation expense for the year ended September 30, 2025 was \$227,639.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 6 - INTANGIBLE ASSETS

Intangible assets consist of the following at September 30, 2025:

Trademark registration costs	\$ 163,030
Less accumulated amortization	<u>(118,591)</u>
	<u>\$ 44,439</u>

Amortization expense for the year ended September 30, 2025 was \$13,600.

Amortization expense for the next four years and thereafter is expected to be as follows:

<u>Years Ending September 30,</u>	
2026	\$ 13,898
2027	11,707
2028	10,325
2029	<u>8,509</u>
	<u>\$ 44,439</u>

NOTE 7 - RIGHT-OF-USE ASSETS AND LIABILITIES

Operating Lease - On August 4, 2021, the Foundation entered into a lease agreement for its office space in North Hollywood, California. The new lease agreement commenced on December 1, 2021, and ends on March 31, 2029. The lease agreement contains one five-year renewal option at fair value. Management does not include the option term in determining the lease period. Also, management estimates the discount rate at 3.25% and amortizes the lease liability using the effective interest method over the 88-month term.

On April 25, 2024, the Foundation entered into a lease expansion agreement for its current office space. The Foundation will pay an additional \$3,950 per month for the additional space with 3.00% rent increases every May. The leasing period for the additional space commenced on May 15, 2024, and ends on March 31, 2029. Management estimates the discount rate at 4.03% and amortizes the lease liability using the effective interest method over the 58-month term.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 7 - RIGHT-OF-USE ASSETS AND LIABILITIES - (CONTINUED)

Maturities of lease liabilities as of September 30, 2025, were as follows:

<u>Years Ending September 30,</u>		
2026	\$	196,850
2027		202,756
2028		208,838
2029		<u>106,826</u>
Total minimum lease payments		715,270
Less: Imputed interest		<u>(43,042)</u>
	\$	<u>672,228</u>

Rent expense (including parking, maintenance, and other occupancy charges) for the year ended September 30, 2025 was \$227,627.

NOTE 8 - COMMITMENTS AND CONTINGENCIES

Grants - The Foundation funds several research grants each year. These awards are for doctors or researchers doing work in the field of multiple myeloma. These grants are awarded annually as one-year awards and are accrued when approved by the Board. During the year ended September 30, 2025, the Foundation accrued \$212,000.00 in grant awards. The payment of research grants is subject to the grant recipient performing the proposed work, providing a report, and submitting request for payment.

Contractual Commitments - The Foundation contracts with university research institutions to provide specific research projects. These amounts are awarded on executory contracts that require specific performance and project activities. The Foundation has future minimum commitments to fund research projects that are summarized as follows:

<u>Years Ending September 30,</u>		
2026	\$	-
2027		181,257
2028		<u>132,300</u>
	\$	<u>313,557</u>

Lines of Credit - The Foundation maintains two borrowing lines of credit for \$400,000 and \$3.4 million which renew on month-to-month bases. The interest rates on outstanding borrowings varies with the lender's prime rate, and was approximately 8.25% and 5.67%, respectively, at September 30, 2025. The amount available under the \$3.4 million line of credit is based on a percentage of investments held in a brokerage account with the lender. The available borrowing amount will fluctuate with the value of investments that are held as collateral. There were no outstanding borrowings at any time during the year ended September 30, 2025.

INTERNATIONAL MYELOMA FOUNDATION
(A California Nonprofit Public Benefit Corporation)
Notes to Financial Statements
September 30, 2025

NOTE 9 – RELATED PARTY TRANSACTIONS

For the year ended September 30, 2025, the Foundation received contributions from certain board members totaling \$635,000.

NOTE 10 - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions as of September 30, 2025 was comprised of the following:

	<u>Beginning of Year</u>	<u>Increase</u>	<u>Releases</u>	<u>End of Year</u>
Program Grants	\$ 199,072	\$ 1,235,000	\$ (1,279,072)	\$ 155,000
Restricted Individual Gifts	-	1,520,700	(1,060,700)	460,000
Gift Annuity Program	123,344	14,985	-	138,329
Fundraising Event	-	636,723	(636,723)	-
	<u>\$ 322,416</u>	<u>\$ 3,407,408</u>	<u>\$ (2,976,495)</u>	<u>\$ 753,329</u>

The following is a summary of changes in the net annuity assets and liabilities during the year ended September 30, 2025:

Assets:

Beginning of the year	\$ 171,382
Investment income	13,723
Payments made to annuitants	(7,810)
Account fees	(1,242)
Transfer from cash account	7,810
	<u>183,863</u>

Assets - End of the year

183,863

Liabilities:

Beginning of year	48,037
Change in annuity obligation	5,307
Payments made to annuitants	(7,810)
	<u>45,534</u>

Liability - End of the year

45,534

Net Annuity Assets

\$ 138,329

Annuity assets were invested in cash (\$1,614), mutual funds (\$87,264), and exchange-traded funds (\$94,985).